Sundeep Dev, MD, FASRS

Vitreoretinal specialist at Retina Consultants of Minnesota (Minneapolis) and an active clinical-trial investigator in retinal vascular and macular disease.

Articles by Sundeep Dev, MD, FASRS

ASRS 2026: initiating aflibercept 8 mg or faricimab earlier improves durability and anatomic outcomes in real-world practice

BySundeep Dev, MD, FASRS,Lucia Gambuzza

July 16th 2026

Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior anatomic outcomes in a real-world analysis of more than 12,000 eyes.

Sundeep Dev, MD, FASRS

Articles by Sundeep Dev, MD, FASRS

ASRS 2026: initiating aflibercept 8 mg or faricimab earlier improves durability and anatomic outcomes in real-world practice

Latest Updated Articles

Trending on Eye Care Network - Ophthalmology Times

Root cause–based dry eye classification and the shift toward precision medicine

Access Challenges in Retinal Vascular Diseases

Managing Retinal Vascular Diseases in Clinical Practice